NCT03562182

Brief Summary

Neonatal respiratory distress syndrome affects babies who are born preterm and requires them to be placed on a ventilator in the Intensive Care Unit. Over 15 million babies were born premature and these numbers have been increasing. It is caused by lungs which are still too immature to produce adequate amounts of surfactant. This surfactant reduces the alveolar surface tension and maintains the alveoli from collapsing. Collapsed alveoli prevent gas exchange and greatly increase work of breathing. Surfactant is a biochemical complex made up mostly of phospholipids such as phosphatidylcholine and phosphatidylglycerol and these, in turn, appear to be synthesized by lysophosphatidylcholine acyltransferase 1 (LPCAT 1). The investigators have previously established that hLPCAT1 mRNA in maternal serum correlates with lamellar body count, a well established clinical marker of fetal lung maturity.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 9, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

June 18, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 19, 2018

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
Last Updated

October 5, 2021

Status Verified

October 1, 2021

Enrollment Period

3.9 years

First QC Date

May 9, 2018

Last Update Submit

October 4, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in LPCAT1 mRNA levels in maternal plasma after antenatal steroid administration

    The investigators will measure the level of LPCAT1 mRNA in maternal plasma before and after the administration of antenatal steroids.

    The time points will be a baseline before steroids, 24h after the first dose, 24h after the second dose, a week after steroids and two weeks after steroids.

Secondary Outcomes (2)

  • Number of participants admitted to the NICU with high LPCAT1 mRNA levels

    Through study completion, within 2 months

  • Correlate the LPCAT1 mRNA copy number to need for intubation in the nicu

    Through study completion, within 2 months

Study Arms (2)

Women Receiving Antenatal Steroids

Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.

Other: blood draw

Normal Pregnancy Controls

1\) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.

Other: blood draw

Interventions

Blood draw (2.5mL) to assess mRNA LPCAT1 levels

Normal Pregnancy ControlsWomen Receiving Antenatal Steroids

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant women
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Patients who seek obstetrical care at Wayne State/DMC

You may qualify if:

  • Singleton pregnancy, no evidence of diabetes, hypertension, smoking, BMI \> 35, Hgb \< 10 g/dl or other confounding variables

You may not qualify if:

  • Smoking, abnormal gestation, multiple gestatio

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Detroit Medical Ceter

Detroit, Michigan, 48201, United States

RECRUITING

Related Publications (4)

  • Welch RA, Recanati MA, Welch KC, Shaw MK. Maternal plasma LPCAT 1 mRNA correlates with lamellar body count. J Perinat Med. 2018 May 24;46(4):429-431. doi: 10.1515/jpm-2017-0057.

  • Harayama T, Shindou H, Shimizu T. Biosynthesis of phosphatidylcholine by human lysophosphatidylcholine acyltransferase 1. J Lipid Res. 2009 Sep;50(9):1824-31. doi: 10.1194/jlr.M800500-JLR200. Epub 2009 Apr 21.

  • Welch RA, Shaw MK, Welch KC. Amniotic fluid LPCAT1 mRNA correlates with the lamellar body count. J Perinat Med. 2016 Jul 1;44(5):531-2. doi: 10.1515/jpm-2015-0008.

  • Ellis B, Kaercher L, Snavely C, Zhao Y, Zou C. Lipopolysaccharide triggers nuclear import of Lpcat1 to regulate inducible gene expression in lung epithelia. World J Biol Chem. 2012 Jul 26;3(7):159-66. doi: 10.4331/wjbc.v3.i7.159.

Biospecimen

Retention: SAMPLES WITH DNA

LPCAT1 mRNA extracted from maternal plasma

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Maurice Recanati, MD

    Assistant Professor OBGYN

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maurice Recanati, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
15 Weeks
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, Clinical Educator

Study Record Dates

First Submitted

May 9, 2018

First Posted

June 19, 2018

Study Start

June 18, 2018

Primary Completion

May 1, 2022

Study Completion

May 1, 2022

Last Updated

October 5, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

No plan to share data

Locations